On Wednesday, Northwest Biotherapeutics, Inc (NASDAQ:NWBO)’s shares inclined 1.62% to $10.04.
Northwest Biotherapeutics, Inc (NWBO) presented the updated data from its ongoing Phase I trial of DCVax-Direct for solid tumors at ASCO this Saturday.
Overview of the Phase I Trial
All patients enrolled in the Phase I trial had late stage cancers, with an average of three inoperable tumors. The patients had failed multiple prior therapies and had a poor prognosis.
As of the reporting date at the ASCO, the trial enrolled 40 patients, and 39 were evaluable. Although the patients had multiple inoperable tumors, only 1 tumor was injected with DCVax-Direct. The treatments comprised of only 3 injections in the first 2 weeks (Day 0, 7 and 14), and up to 3 additional injections spaced months apart thereafter (Weeks 8, 16 and 32), over a total period of 8 months.
Patients typically received their first injection about 1-1/2 months after recruitment. Four patients are still in the process of concluding the study visits, and data collection is ongoing on all of the patients.
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Zayo Group Holdings Inc (NYSE:ZAYO)’s shares gained 2.16% to $26.43.
Zayo Group Holdings Inc (ZAYO) declares that it has been recognized at the City of London’s Considerate Contractor Scheme awards for its work across the City during the past 12 months. Zayo won gold in the Streetworks category, making 2015 the third successive year the company has been honored.
The Considerate Contractor Scheme, founded by the City of London in 1987, works to encourage building and civil engineering contractors working in the City to operate in a safe and considerate manner, taking into account other users. Winners are judged on a code of good practice, which incorporates public comments. The code requires that they operate with care, cleanliness, considerateness and cooperativeness, taking into account comments from members of the public.
Zayo Group Holdings, Inc., through its auxiliaries, provides bandwidth infrastructure solutions for the communications industry in the United States and Europe. The company operates in three segments: Physical Infrastructure, Lit Services, and Other. The Physical Infrastructure segment provides dark fiber, fiber-to-the-tower and small cell mobile infrastructure, and colocation and interconnection services for carriers and other communication service providers, Internet service providers, wireless service providers, media and content companies, large enterprises, and other companies.
At the end of Wednesday’s trade, Becton, Dickinson and Co. (NYSE:BDX)‘s shares surged 1.54% to $140.05.
Becton, Dickinson and Co. (BDX) declared the successful implementation of the Alaris® System across all four WellSpan hospitals, with WellSpan York Hospital becoming the first hospital ever to simultaneously go-live with new infusion devices and bi-directional interoperability between the infusion device and the electronic health record (EHR).
Infusion device interoperability connects the health system’s Alaris System smart infusion pumps with the hospital’s EHR and is designed to assist reduce the risk of harmful and costly intravenous (IV) medication programming errors at the patient bedside. The solution enables bi-directional communication between the infusion pump and the EHR for both syringe pumps and large volume infusions.
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The companys BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Life Sciences segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers.
King Digital Entertainment PLC (NYSE:KING), ended its Wednesday’s trading session with 0.40% gain, and closed at $14.93.
King Digital Entertainment PLC (KING) declared the launch of its first word-based ‘Saga’ game, AlphaBetty Saga. Now accessible to download for free from the AppStore and Google Play, this new game challenges players to take an exciting journey into the world of words, accompanied by an adventurous band of mice.
AlphaBetty Saga sets players off on a bold new quest as Betty, a young mouse living in the 1930s, follows her grandfather, Professor Alpha, and his loyal assistant, Barney, to discover lost words to complete the “Encyclopedia of Everything”. As the world’s authority on collecting words, Professor Alpha will call on players to assist him complete the legendary book.
This vibrant word-based game uses non-linear gameplay to enhance creative word play and planned opportunities for players as they are tasked with connecting adjacent letters to create words, score points and ultimately advance through a world very much like our own except for one small detail – it’s inhabited by mice and much of it is made of cheese!
King Digital Entertainment plc, an interactive entertainment company, produces and distributes digital games on multiple platforms in the United States, the United Kingdom, Germany, and internationally. The company primarily provides Candy Crush Saga, Candy Crush Soda Saga, Farm Heroes Saga, Pet Rescue Saga, and Bubble Witch 2 Saga games.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
